546 results on '"Chao, Jingdong"'
Search Results
2. Development, Psychometric Validation and Responder Definition of Worst Itch Scale in Children with Severe Atopic Dermatitis
3. Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE)
4. Evaluating the clinical utility of the Atopic Dermatitis Control Tool: measurement properties and agreement between patients’ responses and clinicians’ impressions of atopic dermatitis control
5. Content validity of a newly developed observer-reported measure for pediatric asthma in children aged 2–5 years
6. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases
7. Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis
8. Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment
9. Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis
10. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma
11. Dupilumab Improves Treatment Satisfaction and Health-Related Quality of Life in Adults with Atopic Dermatitis in Clinical Practice: Subgroup Analysis of Black/African American Population from RELIEVE-AD
12. Dupilumab Improves Disease Control and Patient-Reported Outcomes in Adults with Atopic Dermatitis in Clinical Practice: Subgroup Analysis of Black/African American Population from RELIEVE-AD
13. Dupilumab Decreases Concomitant Therapy use in Adults with Atopic Dermatitis in Clinical Practice: Subgroup Analysis of Black/African American Population from RELIEVE-AD
14. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis
15. Development and validation of a caregiver-reported Numeric Rating Scale for measuring worst scratch/itch in patients aged 6 months to younger than 6 years with atopic dermatitis
16. Development and validation of a caregiver-reported Numeric Rating Scale for measuring worst scratch/itch in patients aged 6 months to younger than 6 years with atopic dermatitis.
17. Health Care Resource Utilization and Costs Among Adults with Atopic Dermatitis in the United States: A Claims-Based Analysis
18. Healthcare Providers Underestimate Patients’ Glucocorticoid Use in Crohn’s Disease
19. Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn’s Disease
20. Efficacy of dupilumab in moderate and severe atopic dermatitis
21. Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons
22. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma
23. Increased Risk of Venous Thromboembolic Events With Corticosteroid vs Biologic Therapy for Inflammatory Bowel Disease
24. 33322 Dupilumab improves patient-reported outcomes among adults with moderate-to-severe atopic dermatitis (AD) in clinical practice: 30-36 month results from the RELIEVE-AD study
25. 33120 Early and sustained improvement in atopic dermatitis (AD) disease control and treatment satisfaction with dupilumab in clinical practice: Long-term data from the RELIEVE-AD study
26. Patient Preferences for Attributes of Biologic Treatments in Moderate to Severe Asthma: A Discrete Choice Experiment Study
27. 32929 Dupilumab decreases concomitant therapy use in adults with atopic dermatitis (AD): Long-term data from the RELIEVE-AD study
28. 33325 Long-term dupilumab effectiveness on health-related quality of life (HRQoL) and work productivity in atopic dermatitis (AD): Results from RELIEVE-AD
29. Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases
30. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease
31. 690 - SCORAD severity band threshold analysis from dupilumab clinical trials in adults with moderate-to-severe atopic dermatitis.
32. Adherence to and Persistence with Adalimumab Therapy among Swedish Patients with Crohn’s Disease
33. Adalimumab Induces Deep Remission in Patients With Crohn's Disease
34. Indirect Costs and Family Burden of Pediatric Crohnʼs Disease in the United States
35. Comparison of Health Care Utilization and Costs Between Patients with Perianal Fistulizing Crohnʼs Disease Treated with Biologics with or Without Previous Seton Placement
36. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial
37. Nomenclature and Traceability Debate for Biosimilars: Small-Molecule Surrogates Lend Support for Distinguishable Nonproprietary Names
38. Response to the correspondence: “Non-optimal methodology questions indirect treatment comparison of dupilumab vs other biologics in severe asthma”
39. Response to comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma (Respir. Med. 2020)
40. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease
41. Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment
42. Adalimumab real-world dosage pattern and predictors of weekly dosing: Patients with Crohn's disease in the United States
43. Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
44. Data Mining of Free-Text Responses: An Innovative Approach to Analyzing Patient Perspectives on Treatment for Chronic Rhinosinusitis with Nasal Polyps in a Phase IIa Proof-of-Concept Study for Dupilumab
45. 27375 Dupilumab provides early and sustained improvement of sleep disturbance in children ≥ 6 years with severe atopic dermatitis (AD) and adolescents with moderate-to-severe AD
46. 27394 Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial
47. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
48. Greater refill adherence to adalimumab therapy for patients using specialty versus retail pharmacies
49. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn’s disease patients
50. Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn’s Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.